Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40


Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.

Zhao J, Guerrero A, Kelnar K, Peltier HJ, Bader AG.

Lung Cancer. 2017 Jun;108:96-102. doi: 10.1016/j.lungcan.2017.02.020. Epub 2017 Mar 1.


Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS.

Invest New Drugs. 2017 Apr;35(2):180-188. doi: 10.1007/s10637-016-0407-y. Epub 2016 Dec 5.


In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW.

Mol Ther Nucleic Acids. 2015 Dec 15;4:e270. doi: 10.1038/mtna.2015.47.


PDL1 Regulation by p53 via miR-34.

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW.

J Natl Cancer Inst. 2015 Nov 17;108(1). pii: djv303. doi: 10.1093/jnci/djv303. Print 2016 Jan.


A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic.

Kelnar K, Bader AG.

Methods Mol Biol. 2015;1317:125-33. doi: 10.1007/978-1-4939-2727-2_8.


A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ.

Oncogene. 2015 Jul;34(27):3547-55. doi: 10.1038/onc.2014.282. Epub 2014 Sep 1.


Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE, Welsh JW.

Mol Ther. 2014 Aug;22(8):1494-1503. doi: 10.1038/mt.2014.79. Epub 2014 May 5.


In-depth analysis shows synergy between erlotinib and miR-34a.

Zhao J, Kelnar K, Bader AG.

PLoS One. 2014 Feb 14;9(2):e89105. doi: 10.1371/journal.pone.0089105. eCollection 2014.


miR-888: hit it when you see it!

Bader AG.

Cell Cycle. 2014;13(3):351. doi: 10.4161/cc.27550. Epub 2013 Dec 17. No abstract available.


Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates.

Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, Bader AG.

Anal Chem. 2014 Feb 4;86(3):1534-42. doi: 10.1021/ac403044t. Epub 2014 Jan 17.


TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.).

Zhao J, Lammers P, Torrance CJ, Bader AG.

Mol Ther. 2013 Sep;21(9):1678-86. doi: 10.1038/mt.2013.148. Epub 2013 Jun 18.


miR-34 - a microRNA replacement therapy is headed to the clinic.

Bader AG.

Front Genet. 2012 Jul 2;3:120. doi: 10.3389/fgene.2012.00120. eCollection 2012.


Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo.

Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A.

Leukemia. 2012 Nov;26(11):2421-4. doi: 10.1038/leu.2012.110. Epub 2012 Apr 23. No abstract available.


Developing therapeutic microRNAs for cancer.

Bader AG, Brown D, Stoudemire J, Lammers P.

Gene Ther. 2011 Dec;18(12):1121-6. doi: 10.1038/gt.2011.79. Epub 2011 Jun 2. Review.


Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ.

Mol Ther. 2011 Jun;19(6):1116-22. doi: 10.1038/mt.2011.48. Epub 2011 Mar 22.


The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG.

Nat Med. 2011 Feb;17(2):211-5. doi: 10.1038/nm.2284. Epub 2011 Jan 16.


The promise of microRNA replacement therapy.

Bader AG, Brown D, Winkler M.

Cancer Res. 2010 Sep 15;70(18):7027-30. doi: 10.1158/0008-5472.CAN-10-2010. Epub 2010 Aug 31. Review.


Phosphatidylinositol 3-kinase: the oncoprotein.

Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A.

Curr Top Microbiol Immunol. 2010;347:79-104. doi: 10.1007/82_2010_80. Review.


Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.

Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG.

Cancer Res. 2010 Jul 15;70(14):5923-30. doi: 10.1158/0008-5472.CAN-10-0655. Epub 2010 Jun 22.


Regression of murine lung tumors by the let-7 microRNA.

Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ.

Oncogene. 2010 Mar 18;29(11):1580-7. doi: 10.1038/onc.2009.445. Epub 2009 Dec 7.


Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.

Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T.

Mol Ther. 2010 Jan;18(1):181-7. doi: 10.1038/mt.2009.207. Epub 2009 Sep 8.


TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motif.

Karagiannidis AI, Bader AG, Hartl M, Bister K.

Virology. 2008 Sep 1;378(2):371-6. doi: 10.1016/j.virol.2008.06.001. Epub 2008 Jul 7.


The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ.

Cell Cycle. 2008 Mar 15;7(6):759-64. Epub 2008 Mar 3.


Applying small RNA molecules to the directed treatment of human diseases: realizing the potential.

Pappas TC, Bader AG, Andruss BF, Brown D, Ford LP.

Expert Opin Ther Targets. 2008 Jan;12(1):115-27. Review.


Phosphorylation by Akt disables the anti-oncogenic activity of YB-1.

Bader AG, Vogt PK.

Oncogene. 2008 Feb 14;27(8):1179-82. Epub 2007 Aug 20.


PI 3-kinases: hidden potentials revealed.

Vogt PK, Bader AG, Kang S.

Cell Cycle. 2006 May;5(9):946-9. Epub 2006 May 1.


Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Bader AG, Kang S, Vogt PK.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1475-9. Epub 2006 Jan 23.


Phosphoinositide 3-kinase: from viral oncoprotein to drug target.

Vogt PK, Bader AG, Kang S.

Virology. 2006 Jan 5;344(1):131-8. Review.


Oncogenic PI3K deregulates transcription and translation.

Bader AG, Kang S, Zhao L, Vogt PK.

Nat Rev Cancer. 2005 Dec;5(12):921-9. Review.


Jun: stealth, stability, and transformation.

Vogt PK, Bader AG.

Mol Cell. 2005 Aug 19;19(4):432-3. Review.


Mutated PI 3-kinases: cancer targets on a silver platter.

Kang S, Bader AG, Zhao L, Vogt PK.

Cell Cycle. 2005 Apr;4(4):578-81. Epub 2005 Apr 7. Review.


Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

Kang S, Bader AG, Vogt PK.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7. Epub 2005 Jan 12.


An essential role for protein synthesis in oncogenic cellular transformation.

Bader AG, Vogt PK.

Oncogene. 2004 Apr 19;23(18):3145-50. Review.


Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway.

Bader AG, Felts KA, Jiang N, Chang HW, Vogt PK.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12384-9. Epub 2003 Oct 6.


Molecular targets of the oncogenic transcription factor jun.

Hartl M, Bader AG, Bister K.

Curr Cancer Drug Targets. 2003 Feb;3(1):41-55. Review.


JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesis.

Hartl M, Reiter F, Bader AG, Castellazzi M, Bister K.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13601-6. Epub 2001 Nov 6.


Supplemental Content

Loading ...
Support Center